Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11075254 | 0.83 | L3MBTL1 (0.42) | ALDH1A1LMNANPSR1L3MBTL1THRB | |
| Cyclohexane SCHEMBL6438104 | 0.82 | ALDH1A1 (0.67) | ALDH1A1LMNAHSD17B10L3MBTL1THRB | |
| Cyclohexane SCHEMBL8362005 | 0.81 | ALDH1A1 (0.64) | ALDH1A1LMNAHSD17B10L3MBTL1THRB | |
| Cyclohexane SCHEMBL27782650 | 0.79 | ALDH1A1 (0.61) | ALDH1A1LMNAHSD17B10L3MBTL1THRB | |
| Biphenyl SCHEMBL28087429 | 0.79 | ALDH1A1 (0.61) | ALDH1A1LMNAHSD17B10NPSR1L3MBTL1 | |
| Cyclohexane SCHEMBL855765 | 0.78 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10L3MBTL1THRB | |
| Cyclohexane SCHEMBL416739 | 0.78 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10L3MBTL1THRB | |
| Cyclohexane SCHEMBL5908851 | 0.78 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10L3MBTL1THRB | |
| Cyclohexane SCHEMBL15635357 | 0.78 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10L3MBTL1THRB | |
| Cyclohexane SCHEMBL509553 | 0.78 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10L3MBTL1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309179-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA (FR) | 2016-04-12 | — | — | US | disclosed |
| US-20140213589-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | FAB PHARMA S.A.S. (FR) | 2014-07-31 | — | — | US | disclosed |
| US-8722746-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA S.A.S. (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8513250-B2 | Imidazolo-heteroaryl derivatives with antibacterial properties | LABORATOIRE BIODIM (FR) | 2013-08-20 | — | — | US | disclosed |
| US-8227511-B2 | Substituted chromanol derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2010-05-27 | — | — | US | disclosed |
| US-20100041658-A1 | Hydroxyphenyl Derivatives and Biological Applications Thereof | FAB PHARMA (FR) | 2010-02-18 | — | — | US | disclosed |
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-7078414-B2 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-18 | — | — | US | disclosed |
| US-6900194-B1 | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2005-05-31 | — | — | US | disclosed |
| EP-1523480-A2 | DERIVATIVES OF 3-GUANIDINOCARBONYL-1-HETEROARYL-PYRROLE, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | Aventis Pharma Deutschland GmbH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-20040266775-A1 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-30 | — | — | US | disclosed |
| WO-2004007478-A2 | DERIVATIVES OF 3-GUANIDINOCARBONYL-1-HETEROARYL-PYRROLE, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-22 | — | — | WO | disclosed |
| EP-1110552-A1 | Use of a compound with affinity for the mitochondrial benzodiazepine receptor in cancer therapy | Aventis Pharma S.A. (FR) | 2001-06-27 | — | — | EP | disclosed |
| US-5385931-A | Multistage formation of sulfonamides by reaction of esters and acyl halides, nitriding, reduction and sulfonylation to form cardiovascular compounds | PIERRE FABRE MEDICAMENT (FR) | 1995-01-31 | — | — | US | disclosed |
| US-4479966-A | 6,9-Methano-PGI2 analogues | ONO PHARMACEUTICAL COMPANY, LTD. (JP) | 1984-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | CYP46A1, CBX3, CDYL | ALDH1A1 1180/4885LMNA 98/4885HSD17B10 424/4885 |
| US-20140213589-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | HPD, HPGDS, EPX | ALDH1A1 171/4885LMNA 3256/4885HSD17B10 165/4885 |
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | DLAT, DLST, DNTT | ALDH1A1 1002/4885LMNA 4169/4885HSD17B10 456/4885 |
| US-20100041658-A1 | Hydroxyphenyl Derivatives and Biological Applications Thereof | HPD, HPGDS, EPX | ALDH1A1 171/4885LMNA 3256/4885HSD17B10 165/4885 |
| US-20040266775-A1 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | GPBAR1, ADRB3, ADRA1A | ALDH1A1 266/4885LMNA 1140/4885HSD17B10 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.